FATE
Price
$1.66
Change
-$0.00 (-0.00%)
Updated
Dec 24 closing price
67 days until earnings call
INZY
Price
$2.93
Change
-$0.08 (-2.66%)
Updated
Dec 24 closing price
84 days until earnings call
Ad is loading...

FATE vs INZY

Header iconFATE vs INZY Comparison
Open Charts FATE vs INZYBanner chart's image
Fate Therapeutics
Price$1.66
Change-$0.00 (-0.00%)
Volume$1.03M
CapitalizationN/A
Inozyme Pharma
Price$2.93
Change-$0.08 (-2.66%)
Volume$292.59K
CapitalizationN/A
FATE vs INZY Comparison Chart
Loading...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INZY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
FATE vs. INZY commentary
Dec 26, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FATE is a Buy and INZY is a Buy.

Ad is loading...
COMPARISON
Comparison
Dec 26, 2024
Stock price -- (FATE: $1.66 vs. INZY: $2.93)
Brand notoriety: FATE and INZY are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FATE: 30% vs. INZY: 50%
Market capitalization -- FATE: $189.06M vs. INZY: $188.22M
FATE [@Biotechnology] is valued at $189.06M. INZY’s [@Biotechnology] market capitalization is $188.22M. The market cap for tickers in the [@Biotechnology] industry ranges from $385.62B to $0. The average market capitalization across the [@Biotechnology] industry is $2.45B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FATE’s FA Score shows that 1 FA rating(s) are green whileINZY’s FA Score has 1 green FA rating(s).

  • FATE’s FA Score: 1 green, 4 red.
  • INZY’s FA Score: 1 green, 4 red.
According to our system of comparison, INZY is a better buy in the long-term than FATE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FATE’s TA Score shows that 2 TA indicator(s) are bullish while INZY’s TA Score has 3 bullish TA indicator(s).

  • FATE’s TA Score: 2 bullish, 6 bearish.
  • INZY’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, INZY is a better buy in the short-term than FATE.

Price Growth

FATE (@Biotechnology) experienced а -11.70% price change this week, while INZY (@Biotechnology) price change was -0.34% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.85%. For the same industry, the average monthly price growth was -1.81%, and the average quarterly price growth was +3.32%.

Reported Earning Dates

FATE is expected to report earnings on Mar 03, 2025.

INZY is expected to report earnings on Mar 20, 2025.

Industries' Descriptions

@Biotechnology (-0.85% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
FATE($189M) and INZY($188M) have the same market capitalization . INZY YTD gains are higher at: -31.221 vs. FATE (-55.615). INZY has higher annual earnings (EBITDA): -90.3M vs. FATE (-177.57M). FATE has more cash in the bank: 297M vs. INZY (132M). INZY has less debt than FATE: INZY (46.8M) vs FATE (99M). FATE has higher revenues than INZY: FATE (13.4M) vs INZY (0).
FATEINZYFATE / INZY
Capitalization189M188M101%
EBITDA-177.57M-90.3M197%
Gain YTD-55.615-31.221178%
P/E RatioN/AN/A-
Revenue13.4M0-
Total Cash297M132M225%
Total Debt99M46.8M212%
FUNDAMENTALS RATINGS
FATE: Fundamental Ratings
FATE
OUTLOOK RATING
1..100
82
VALUATION
overvalued / fair valued / undervalued
1..100
18
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
95
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
FATEINZY
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
88%
Momentum
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 17 days ago
86%
Bullish Trend 3 days ago
86%
Declines
ODDS (%)
Bearish Trend 7 days ago
90%
Bearish Trend 8 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INZY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
REPIX41.680.43
+1.04%
ProFunds Real Estate UltraSector Inv
RPRCX8.270.08
+0.98%
Royce Premier Consult
IBCGX20.960.11
+0.53%
VY® Baron Growth S2
JEVCX8.790.04
+0.46%
JHancock Disciplined Value Em Mkts Eq C
PWJCX27.180.06
+0.22%
PGIM Jennison International Opps C

FATE and

Correlation & Price change

A.I.dvisor indicates that over the last year, FATE has been loosely correlated with ALLO. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if FATE jumps, then ALLO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FATE
1D Price
Change %
FATE100%
N/A
ALLO - FATE
58%
Loosely correlated
+7.18%
RCKT - FATE
51%
Loosely correlated
+2.19%
CCCC - FATE
51%
Loosely correlated
-4.68%
CRBU - FATE
50%
Loosely correlated
-5.59%
NTLA - FATE
50%
Loosely correlated
-0.41%
More

INZY and

Correlation & Price change

A.I.dvisor indicates that over the last year, INZY has been loosely correlated with BEAM. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if INZY jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INZY
1D Price
Change %
INZY100%
-2.66%
BEAM - INZY
58%
Loosely correlated
+0.38%
NAUT - INZY
53%
Loosely correlated
+0.58%
ABOS - INZY
50%
Loosely correlated
+1.13%
DNLI - INZY
48%
Loosely correlated
+0.67%
PLRX - INZY
47%
Loosely correlated
+1.12%
More